Philip Rowe

🚨 The Isotope Wars in Radiopharma - who wins? → The field has 300+ therapeutic RLT trials active right now. → But the constraint is no longer molecules. → It’s atoms. ⚛️ Lu-177 → Scaled but Fragile Capacity looks abundant: Novartis, ITM Isotope Technologies Munich SE, SHINE Technologies, Curium Pharma have all scaled reactor output. On paper, supply is “unconstrained.” But resilience still depends on: • A handful of aging European reactors • Enriched Yb-176 - historically Russian, only now diversifying One outage or geopolitical hiccup, and the chain cracks. 🔥 Ac-225 → The Existential Choke Point Global supply remains in low single-digit curies per year. Even if U.S. Department of Energy (DOE), TerraPower, NorthStar Medical Radioisotopes, LLC, BWXT, ITM Isotope Technologies Munich SE, and Eckert & Ziegler SE all scale… 👉 One successful PSMA launch could swallow most of it overnight. That’s why investors are actively funding hedges: Pb-212, At-211, Tb-161, Cu-67. ☢️ Pb-212 → Industrial Scale in Sight Orano Med is leading the way. → With parent Orano’s thorium supply, they control the feedstock others lack. → Their Alpha Therapy Labs in the US and France target >10,000 doses/year by mid-decade, scaling 10× by 2030. → The generator model makes Pb-212 a true hedge against Ac-225 scarcity - and Orano Med is the company best placed to deliver it at scale. 🌀 At-211, Cu-67, Tb-161 → Next Plays • At-211: 7.2h half-life → hyper-local cyclotron networks now being built in US/EU. • Cu-67: Moving into clinical supply (Clarity Pharmaceuticals ↔ Nucleus RadioPharma deal), with Nusano targeting production in its new facility build-out (2025–26). • Tb-161: “Lu-177-plus” physics, but depends on scarce Gd-160 enrichment - only now diversifying outside Russia/China. 🏭 Vertical Integration = The Moat This is the pattern: • Novartis building its own isotope lines • Eli Lilly and Company acquiring POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company • Lantheus buying Evergreen Theragnostics • ASP Isotopes scaling Yb-176 & Gd-160 enrichment • Orano Med - uniquely de-risked, with parent Orano’s thorium supply enabling secured Pb-212 production at industrial scale • Eckert & Ziegler SE expanding Ac-225 and Pb-212 supply chains in Europe The game is shifting from “who has the ligand” → who owns isotope + GMP + logistics. 🔮 The Thesis This isn’t one bottleneck. It’s three simultaneous wars: 1️⃣ Physics - half-lives dictate your business model 2️⃣ Geopolitics - precursor supply concentrated in Russia/China 3️⃣ Capital - only those locking supply with prepaid deals today will still be running by 2027 📈 My Prediction ➡️ By 2027, valuations in radiopharma won’t hinge on clinical data alone. ➡️ They’ll hinge on who survived the isotope wars with supply secured. What's your prediction? #radiopharma #isotopes #RLT #theranostics

571

41 Comments

👨‍🔬💬 𝐂𝐞𝐥𝐥 & 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐢𝐭𝐲: 𝟐𝟔𝐭𝐡 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟓 👩‍🔬💬 🧬 uniQure announced positive topline results from its pivotal Phase I/II study of AMT-130, a gene therapy for Huntington’s disease. High-dose AMT-130 significantly slowed disease progression over 36 months, meeting the primary endpoint and a key secondary endpoint compared to an external control. Favorable trends were observed across cognitive and motor measures, with reduced CSF NfL levels suggesting decreased neurodegeneration. 🧬 Sanofi’s SAR446268, a one-time AAV gene therapy for non-congenital myotonic dystrophy type 1 (DM1), has received FDA Fast Track designation to accelerate its development and review. The therapy uses RNA interference to silence DMPK expression, aiming to remove toxic RNA foci, restore normal splicing, and improve muscle function. It targets key DM1 symptoms, including progressive muscle weakness and myotonia, and addresses systemic effects on heart, lungs, and endocrine function. 🧬 Cure Rare Disease announced that the FDA has granted Orphan Drug Designation for its gene therapy CRD-003 to treat Limb-Girdle Muscular Dystrophy Type R9 (LGMD2i/R9), which currently has no approved treatments. CRD-003 uses an AAV vector to deliver FKRP under a muscle-specific promoter, restoring alpha-dystroglycan glycosylation to maintain muscle integrity. The therapy targets progressive skeletal, cardiac, and CNS muscle weakness caused by FKRP mutations. 🦠 Aspen Neuroscience, Inc. initiated Cohort 3 of its ASPIRO Phase 1/2a trial for ANPD001, a personalized autologous dopaminergic neuronal precursor cell therapy for moderate-to-advanced Parkinson’s disease. This cohort uses Aspen’s commercial formulation, enabling scalable, cryopreserved dosing without immunosuppression. ANPD001 is derived from patient skin cells, reprogrammed into iPSCs and differentiated into dopaminergic cells, delivered via a precision MRI-guided system. 🧬 Intellia Therapeutics, Inc. reported positive longer-term Phase 1 data for nexiguran ziclumeran (nex-z) in hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). A one-time dose achieved deep, durable TTR reductions across patients, including those who had progressed on patisiran. Most patients showed stability or clinically meaningful improvements in neuropathy scores, quality of life, and disability measures. 🦠 Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0) has filed FDA Pre-IND 1517 to advance ACP-01 (VesCell™), its autologous stem cell therapy, via a basket Phase I trial across multiple ischemic and vascular conditions. The basket protocol aims to evaluate safety, feasibility, and early efficacy across indications under a unified design, accelerating development and expanding therapeutic potential. 🛎 My aim is to be the messenger when it comes to your CGT news. Follow #mCGT to stay updated! #celltherapy #genetherapy #ATMP #advancedtherapy

101

1 Comment

🚀 Big pharma money is on the move and small biotechs should be paying attention 🚀 Sanofi Ventures just raised $625M to fuel innovation in rare disease, neurology, immunology, and vaccines. For early-stage biotechs, this could mean survival and speed in a tough funding climate. It also means small companies will need sharper market access and pricing strategies earlier than ever. 👉 Will pharma VCs reshape the biotech funding landscape in 2026?

36

The Changing Role of Biometrics in Pharma Not long ago, biometrics in pharma was viewed as a support function — a back-end team focused mainly on number crunching, data cleaning, and statistical reporting. But that perception has changed dramatically. Today, biometrics is at the heart of decision-making. Biostatisticians, programmers, and data managers are shaping trial design, influencing go/no-go decisions, and helping turn complex clinical data into meaningful insights that accelerate drug development. The modern biometrics professional isn’t just a data expert — they’re a storyteller, translating numbers into narratives that drive smarter, faster, and more patient-focused outcomes. As the industry evolves with AI, decentralised trials, and real-world data integration, the influence of biometrics will only continue to grow. What changes have you seen in how biometrics teams are valued within pharma? JCR Pharma Mathy Bekele Jessica Smith #Biometrics #ClinicalResearch #Biostatistics #DataScience #Pharma #ClinicalTrials #JCRPharma

34

Welcome to 2 Minutes of Insightful Dialogue with a Life Science Expert – September 2025! This month, I’m honoured to speak with Dr Björn Cochlovius, Ph.D., CEO of Eleva Biologics, an expert in strategic reorganisation and preparation for exit. Our topic: “Myths About Pharma Reorganisation and the Real Reasons Behind It.” Our topic: Myths About Pharma Reorganisation and the Real Reasons Behind It. Myth: Reorganisation is just about cutting costs. Reality: In pharma, it’s about positioning for the next 3–10 years, whether scaling for a blockbuster launch, prioritising a high-potential therapeutic asset or ensuring capital efficiency for long development timelines. Example: A company with several programs may pivot resources to a promising oncology treatment, investing in manufacturing and commercial readiness while scaling back lower-priority initiatives. Not always growth-driven: Reorganisation can also be defensive, addressing patent loss, failed trials or regulatory pressures by streamlining, reducing costs or divesting assets. End goal: Build a stronger, more focused company that delivers valuable medicines, sustains revenue and remains competitive whether success comes from one big product or a diverse pipeline. What’s your perspective on pharma reorganisation, growth engine or survival strategy?

28

2 Comments